Moderna’s experimental vaccine against skin cancer received the designation of an innovative therapy from the Food and Drug Administration (FDA), equivalent to Anvisa in the United States, according to the company’s statement on Wednesday (2/22).

The classification is given by the FDA when experimental drugs intended for the treatment of serious diseases are significantly more effective than existing ones. It allows data review and late-stage testing to be accelerated.

Moderna’s vaccine uses mRNA technology – the same used in the US company’s Covid-19 vaccine – in combination with Merck’s Keytruda drug, and is intended for the treatment of high-risk patients.

Keytruda works against the patients’ tumor cells. Moderna’s vaccine hands the keys to the tumor’s DNA signature to the immune system. With this strategy, the T cells are expected to work to fight you if the cancer returns.

Advertising by Metrópoles 1 partner
Advertising by Metrópoles 2 partner
Advertising by Metrópoles 3 partner
Advertising by Metrópoles 4 partner
Advertising by Metrópoles 5 partner
Advertising by Metrópoles 6 partner

0

The results of an interim Phase 2 study by the drugmaker, released in December 2022, showed that the therapy reduced the risk of disease recurrence after surgery by 44% compared to using Keytruda alone.

The two companies informed, through an announcementwho will continue to discuss the results with regulatory authorities and will start a phase 3 study later in 2023. They hope to expand the studies to other tumor types, including non-small cell lung cancer.

Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.

California18

Welcome to California18, your number one source for Breaking News from the World. We’re dedicated to giving you the very best of News.

Leave a Reply